Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

Andrew J. Armstrong; Vinnie Y.T. Liu; Ramprasaath R. Selvaraju; Emmalyn Chen; Jeffry Simko; Sandy DeVries; Oliver Sartor; Howard M. Sandler; Osama Mohamad; Huei–Chung Huang; Jacqueline Griffin; Rikiya Yamashita; Andre Esteva; Phuoc T. Tran; Daniel E. Spratt; John H. Carson; Christopher A. Peters; Elizabeth Gore; Steve P. Lee; Jedidiah M. Monson; Mark E. Augspurger; Ali El‐Gayed; Joseph P. Rodgers; Rana R. McKay; Todd M. Morgan; Felix Y. Feng; Paul L. Nguyen

doi:10.1200/jco.24.00365

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

To our knowledge, the MMAI model is the first validated predictive biomarker to guide ADT duration with RT in localized/locally advanced PCa. Approximately one third of men with high-risk PCa could safely be spared the additional 24 months of ADT and the associated morbidity.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Armstrong et al. (2025) studied this question.

synapsesocial.com/papers/69deabd4077ec87fd1e93e1a https://doi.org/10.1200/jco.24.00365

View Full Paper

Ask AI

Bookmark

Share

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

Ask about this paper

Abstract

Discussion

Cite This Study

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading